Description
| Description | Datopotamab deruxtecan (DS-1062; Dato-DXd) is an antibody-drug conjugate (ADC) that specifically targets trophoblast cell surface antigen 2 (TROP2). This compound exhibits high antitumor activity. |
| In vitro | Datopotamab deruxtecan (Dato-DXd; 100 μg/mL) binds specifically to TROP2 and was internalized into tumor cells followed by intracellular trafficking to lysosome and Deruxtecan release, which induced DNA damage and apoptosis in TROP2-expressing tumor cells in vitro[1]. |
| In vivo | Datopotamab deruxtecan (Dato-DXd; 6 mg/kg) shows potent antitumor activity with tumor regression in several TROP2-expressing xenograft tumors including NSCLC patient-derived xenograft (PDX) models. Safety profiles of Datopotamab deruxtecan in rats and cynomolgus monkeys are acceptable[1]. |
| Synonyms | DS-1062, Dato-DXd |
| Molecular Weight |
N/A |
| CAS No. | 2238831-60-0 |
Storage
store at -20 ℃
Solubility Information
( < 1 mg/ml refers to the product slightly soluble or insoluble )
